22nd Century Group Inc. develops and commercializes reduced-nicotine tobacco products built on proprietary plant biotechnology. Its VLN® combustible cigarette products use low-nicotine tobacco and are described in company materials as FDA-authorized reduced nicotine cigarettes in the United States. Company updates commonly address VLN retail distribution, state authorizations, PMTA-related product expansion, licensing strategy, tobacco-variety research and engagement with FDA and public-health stakeholders.
News also covers operating results for the tobacco business, including branded VLN products, contract manufacturing volumes, filtered cigars and other distributed tobacco products. Recent company reporting frames results around commercial expansion, cost management, higher-margin branded products and the completed exit from the hemp/cannabis business.
22nd Century Group has appointed James A. Mish as the new CEO effective June 22, 2020, and John Franzino as the CFO immediately. Mish brings significant executive leadership experience in pharmaceuticals and cannabinoids, previously leading Noramco and its spinoff, Purisys. The company anticipates growth through its reduced nicotine cigarettes and new cannabinoid products. Franzino, with a background in finance for tobacco and alcoholic beverages, is expected to navigate the company through its growth phase. Former CFO Andrea Jentsch resigned for personal reasons.
Summary not available.